ColoPrint® is an 18-gene expression signature designed to predict disease relapse in patients with early-stage colorectal cancer (CRC). We discuss the potential impact of ColoPrint® on clinical practice, and its contribution to our knowledge of CRC molecular heterogeneity.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Development and validation of an individualized gene expression-based signature to predict overall survival of patients with high-grade serous ovarian carcinoma
European Journal of Medical Research Open Access 27 October 2023
-
Protein expression profiling identifies a prognostic model for ovarian cancer
BMC Women's Health Open Access 15 July 2022
-
A molecular signature for the prediction of recurrence in colorectal cancer
Molecular Cancer Open Access 03 February 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Salazar, R. et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J. Clin. Oncol. doi: 10.1200/JCO.2010.30.1077.
O'Connell, M. J. et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J. Clin. Oncol. 28, 3937–3944 (2010).
O'Connell, J. B., Maggard, M. A. & Ko, C. Y. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J. Natl Cancer Inst. 96, 1420–1425 (2004).
Cunningham, D. et al. Colorectal cancer. Lancet 375, 1030–1047 (2010).
Benson, A. B. 3rd et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol. 22, 3408–3419 (2004).
Wang, Y. et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J. Clin. Oncol. 22, 1564–1571 (2004).
Eschrich, S. et al. Molecular staging for survival prediction of colorectal cancer patients. J. Clin. Oncol. 23, 3526–3535 (2005).
Salazar, R. et al. The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint [abstract]. J. Clin. Oncol. 28 (Suppl. 15), aTPS199 (2010).
Guastadisegni, C., Colafranceschi, M., Ottini, L. & Dogliotti, E. Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur. J. Cancer 4 6, 2788–2798 (2010).
Rosman, M., Mylander, W. C. & Tafra, L. What is the value of the 21 gene recurrence score in HER2-negative patients? J. Clin. Oncol. 28, e647 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Tan, I., Tan, P. An 18-gene signature (ColoPrint®) for colon cancer prognosis. Nat Rev Clin Oncol 8, 131–133 (2011). https://doi.org/10.1038/nrclinonc.2010.229
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.229
This article is cited by
-
Development and validation of an individualized gene expression-based signature to predict overall survival of patients with high-grade serous ovarian carcinoma
European Journal of Medical Research (2023)
-
Protein expression profiling identifies a prognostic model for ovarian cancer
BMC Women's Health (2022)
-
Molecular subtypes in cancers of the gastrointestinal tract
Nature Reviews Gastroenterology & Hepatology (2017)
-
A molecular signature for the prediction of recurrence in colorectal cancer
Molecular Cancer (2015)
